Search - tctmd.com

Displaying 81 - 100 of 251

Sort: Relevancy | Date

News Daily News

Lp(a) Genetics Differ Between Populations but Have Similar Clinical Impact

Yael L. Maxwell

May 05, 2025

News Daily News

HDL Cholesterol Levels May Sway Statin Decisions in Primary Prevention

Michael O'Riordan

May 02, 2025

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for April 2025

Caitlin E. Cox

April 30, 2025

News Daily News

TAVI and Complex/High-Risk PCI Safer if Staged, Registry Confirms

Caitlin E. Cox

April 28, 2025

News Daily News

Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI

Michael O'Riordan

April 22, 2025

News Opinion CV Team Dispatch

April 2025 Dispatch for the CV Team

L.A. McKeown

April 18, 2025

News Daily News

Black Adults Face CV Mortality Beyond Their Predicted Risk

Caitlin E. Cox

April 18, 2025

News Daily News

Cardiotoxicity Rare With Common GI Chemotherapy

L.A. McKeown

April 15, 2025

News Conference News ACC 2025

RACER: No Change in Cardiac Arrests During Marathons, but Survival Is Up

Michael O'Riordan

April 08, 2025

News Conference News ACC 2025

AI Shows Promise in Detecting Type 1 MI and Need for Revascularization

Yael L. Maxwell

April 07, 2025

News Conference News ACC 2025

Nurses Can Be Pivotal in Post-ACS Secondary Prevention: ALLEPRE

Caitlin E. Cox

April 02, 2025

News Conference News ACC 2025

RIVAWAR: Rivaroxaban as Safe and Effective as Warfarin for LV Thrombus in MI

Michael O'Riordan

April 02, 2025

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for March 2025

Caitlin E. Cox

April 01, 2025

News Conference News ACC 2025

PCI Rebounds at 5 Years to Mostly Match CABG: Final FAME 3 Data

Caitlin E. Cox

March 31, 2025

Presentation ACC 2025

Outcomes after FFR-Guided PCI vs. CABG: Final 5-Year Follow-up of the FAME 3 Trial

Presenter: William Fearon

March 30, 2025

News Conference News ACC 2025

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Michael O'Riordan

March 29, 2025

Presentation ACC 2025

Oral Semaglutide Reduces Cardiovascular Events in People with Type 2 Diabetes with Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary Results From the SOUL Randomized Trial

Presenter: Darren K. McGuire

March 29, 2025

Presentation ACC 2025

Dual Antiplatelet Therapy After PCI According To Bleeding Risk: HOST-BR RCT

Presenter: Hyo-Soo Kim

March 29, 2025

Presentation ACC 2025

Clopidogrel versus Aspirin Monotherapy in Patients with High Ischemic Risk after PCI: SMART-CHOICE 3 Trial

Presenter: Joo-Yong Hahn

March 29, 2025

News Conference News ACC 2025

WARRIOR: No Clear Answers on How to Best Treat INOCA

Yael L. Maxwell

March 29, 2025

Advertisement

Lp(a) Genetics Differ Between Populations but Have Similar Clinical Impact

HDL Cholesterol Levels May Sway Statin Decisions in Primary Prevention

TCTMD’s Top 10 Most Popular Stories for April 2025

TAVI and Complex/High-Risk PCI Safer if Staged, Registry Confirms

Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI

April 2025 Dispatch for the CV Team

Black Adults Face CV Mortality Beyond Their Predicted Risk

Cardiotoxicity Rare With Common GI Chemotherapy

RACER: No Change in Cardiac Arrests During Marathons, but Survival Is Up

AI Shows Promise in Detecting Type 1 MI and Need for Revascularization

Nurses Can Be Pivotal in Post-ACS Secondary Prevention: ALLEPRE

RIVAWAR: Rivaroxaban as Safe and Effective as Warfarin for LV Thrombus in MI

TCTMD’s Top 10 Most Popular Stories for March 2025

PCI Rebounds at 5 Years to Mostly Match CABG: Final FAME 3 Data

Outcomes after FFR-Guided PCI vs. CABG: Final 5-Year Follow-up of the FAME 3 Trial

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Oral Semaglutide Reduces Cardiovascular Events in People with Type 2 Diabetes with Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary Results From the SOUL Randomized Trial

Dual Antiplatelet Therapy After PCI According To Bleeding Risk: HOST-BR RCT

Clopidogrel versus Aspirin Monotherapy in Patients with High Ischemic Risk after PCI: SMART-CHOICE 3 Trial

WARRIOR: No Clear Answers on How to Best Treat INOCA

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content